Epigenetics

Epigenetics research delves into the molecular mechanisms that control gene expression and cellular traits without altering the underlying DNA sequence. One crucial aspect of this field is the role of small molecules, which act as powerful regulators of epigenetic modifications. These small compounds, typically comprising a few dozen to a few hundred atoms, have emerged as essential tools in understanding and manipulating the epigenome.

  • DNA Methylation Inhibitors: Small molecules like 5-azacytidine and 5-aza-2'-deoxycytidine are DNA methyltransferase inhibitors. They block the addition of methyl groups to DNA, leading to DNA demethylation. This can reactivate silenced genes, potentially offering therapeutic avenues for conditions like cancer.
  • HDAC inhibitors: HDACs remove acetyl groups from histone proteins, contributing to gene repression. Small molecule HDAC inhibitors, such as Vorinostat and Romidepsin, can reverse this process by increasing histone acetylation, allowing genes to be more accessible for transcription. These inhibitors are being explored for cancer therapy and other conditions.
  • Histone Methyltransferase Inhibitors: Small molecules like GSK126 inhibit specific histone methyltransferases, affecting histone methylation patterns. This can alter gene expression, making them promising candidates for cancer and other diseases with epigenetic dysregulation.
  • RNA Modulators: Small molecules can also target non-coding RNAs involved in epigenetic regulation. For instance, small molecules called small interfering RNAs (siRNAs) can be designed to target and degrade specific long non-coding RNAs, influencing gene expression.
  • Epigenetic Reader Domain Inhibitors: These small molecules target proteins that recognize and bind to specific epigenetic marks. Examples include inhibitors of bromodomain-containing proteins (BET inhibitors), which can disrupt gene regulation by interfering with protein-DNA interactions.

Small molecules in epigenetics research not only provide insights into the fundamental biology of gene regulation but also hold immense promise for developing novel therapeutics. Their ability to selectively modulate specific epigenetic marks and pathways has led to ongoing clinical trials and drug development efforts for various diseases, including cancer, neurological disorders, and inflammatory conditions. Understanding and harnessing the power of these small molecules is at the forefront of modern epigenetics research, offering new hope for precision medicine and targeted therapies.


3 key components involved in the regulation of epigenetic modifications

Epigenetics Writer

Epigenetics writers are enzymes responsible for adding chemical marks or modifications to DNA or histone proteins. These marks include DNA methylation (addition of methyl groups to DNA) and histone modifications (such as acetylation, methylation, phosphorylation, etc.).

Epigenetics Reader

Function: Epigenetics readers are proteins that can recognize and bind to specific epigenetic marks on DNA or histones. These reader proteins interpret the epigenetic code and facilitate downstream cellular processes, such as gene activation or repression.

Epigenetics Eraser

Function: Epigenetics erasers are enzymes responsible for removing or reversing epigenetic marks on DNA or histones. This process allows for the dynamic regulation of gene expression and the resetting of epigenetic states during various stages of development and in response to environmental changes.

Shop By

Items 1901-1950 of 2164

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. BET Inhibitor

    Zavabresib is a potent inhibitor of bromodomain and extraterminal domain (BET) proteins. It exhibits significant anticancer activity, particularly in prostate cancer, demonstrated by IC50 values of 0.043 and 0.034 μM against LNCaP and 22Rv1 cell lines, respectively. This compound is a valuable tool for investigating the role of BET inhibition in cancer biology and therapeutic development.
  2. PLK1/BRD4 Inhibitor

    PLK1/BRD4-IN-2 is a dual inhibitor targeting both Polo-like kinase 1 (PLK1) and the bromodomain of BRD4, with an IC50 of 40 nM and 28 nM, respectively. This compound is valuable for research into cancer therapeutics and epigenetic regulation, demonstrating potential in studies focused on cell proliferation and transcriptional control. Its ability to simultaneously inhibit these key oncogenic pathways positions PLK1/BRD4-IN-2 as a crucial tool for advancing cancer research and drug discovery initiatives.
  3. BET Inhibitor

    BET-IN-14 is a potent pan BET inhibitor with an IC50 of 5.35 nM, designed to inhibit bromodomain and extraterminal (BET) proteins. It exhibits significant anti-cancer activity, making it a valuable tool for cancer research. Its application spans various studies investigating the role of BET proteins in tumorigenesis and the development of targeted cancer therapies.
  4. BET Inhibitor

    ET-JQ1-OH is a selective BET inhibitor that specifically targets bromodomain-containing protein 4 (Brd4). This compound serves as an effective ligand in the design and development of PROTACs, facilitating the targeted degradation of Brd4 and enhancing research in epigenetic regulation and cancer biology. Its applications extend to studies investigating the role of BET proteins in various diseases, providing a valuable tool for researchers in drug discovery and therapeutic advancements.
  5. BRD4 Inhibitor

    BRD4 Inhibitor-24 is a selective inhibitor of the bromodomain-containing protein 4 (BRD4). It exhibits significant antitumor activity, demonstrated by IC50 values of 33.7 μM against MCF7 cells and 45.9 μM against K652 cells. This compound is valuable for research exploring the role of BRD4 in cancer biology and therapeutic development.
  6. BRD4 Inhibitor

    TAT-PiET-PROTAC is a BRD4 inhibitor designed as a proteolysis-targeting chimera (PROTAC) that incorporates the cell-penetrating peptide TAT-PiET. This compound effectively reduces the levels of BRD4 and JMJD6, demonstrating significant inhibition of cell proliferation. TAT-PiET-PROTAC is particularly relevant for investigating endocrine resistance in ERα-positive breast cancer cells, making it a valuable tool for cancer research.
  7. BRD4 Bromodomain Inhibitor

    iBRD4-BD1 diTFA is a selective inhibitor of the BRD4 bromodomain, demonstrating potent inhibitory activity with an IC50 of 12 nM. This compound is valuable for research on inflammation and oncology, particularly in studies aimed at understanding the role of BRD4 in gene regulation and cancer progression. Its specificity and efficacy make it a useful tool for exploring therapeutic strategies targeting the BRD4 pathway.
  8. BRD7/9 Inhibitor

    (2S,3R)-LP99 is a highly selective inhibitor of BRD7 and BRD9, exhibiting a KD of 99 nM for BRD9. This compound effectively disrupts the binding of BRD7 and BRD9 to acetylated histones both in vitro and in cellular environments. (2S,3R)-LP99 is instrumental for research into the regulatory roles of BRD7 and BRD9 in pro-inflammatory cytokine secretion, making it a valuable tool for studies investigating inflammation and epigenetic regulation.
  9. BET Inhibitor

    (+) -JQ-1-aldehyde is an aldehyde derivative of the BET inhibitor (+)-JQ1, specifically targeting the BET bromodomains. This compound serves as a crucial precursor for the synthesis of PROTACs, facilitating the targeted degradation of proteins associated with various cancers and other diseases. Its application in chemical biology research advances the understanding of epigenetic regulation and therapeutic development.
  10. BRD4 Inhibitor

    OXFBD04 is a selective inhibitor of BRD4 with an IC50 of 166 nM. This compound acts as a potent ligand for the BET bromodomain, also exhibiting modest affinity for the CREBBP bromodomain. OXFBD04 demonstrates significant anti-cancer activity, making it a valuable tool for research in cancer biology and therapeutic development targeting epigenetic regulation.
  11. BET Inhibitor

    FT001 is a selective inhibitor of bromodomain and extraterminal (BET) proteins. It exhibits significant anti-proliferative activity against MV-4-11 leukemia cells, making it a valuable tool for cancer research. FT001 can facilitate studies aimed at understanding the role of BET proteins in tumorigenesis and exploring potential therapeutic strategies for hematological malignancies.
  12. BET Bromodomains Inhibitor

    I-BET282E is a selective pan-inhibitor of all eight BET bromodomains, effectively targeting BRD2, BRD3, and BRD4 with pIC50 values ranging from 6.4 to 7.7. This compound demonstrates potent inhibition and selectivity over other bromodomain-containing proteins, making it a valuable tool for investigating the role of BET proteins in cellular processes. I-BET282E is suited for research applications in cancer biology and epigenetic regulation.
  13. BRPF Bromodomain Inhibitor

    GSK9311 hydrochloride is a bromodomain inhibitor targeting BRPF proteins, specifically designed as a less active analogue of GSK6853 for use as a negative control in research. It exhibits inhibitory activity against the BRPF bromodomain, with pIC50 values of 6.0 for BRPF1 and 4.3 for BRPF2. This compound is valuable for studies investigating the role of bromodomain interactions in cellular processes and for validating the effects of more potent bromodomain inhibitors.
  14. BRD4 D1 Inhibitor

    BRD4 D1-IN-1 is a selective inhibitor of the BRD4 D1 domain, demonstrating an IC50 of less than 0.092 µM and an affinity of 18 nM. This compound exhibits over 500-fold selectivity for BRD4 D1 compared to BRD2 D1 and BRD4 D2, as determined by isothermal titration calorimetry (ITC). BRD4 D1-IN-1 is primarily used in research related to cancer and inflammatory diseases, providing insights into the role of BRD4 in transcriptional regulation.
  15. BRD2/3/4 Inhibitor

    I-BET151 dihydrochloride is a selective inhibitor of the bromodomain and extraterminal (BET) family, targeting BRD2, BRD3, and BRD4 with pIC50 values of 6.1, 6.3, and 6.6, respectively. This compound effectively disrupts the interaction between BET proteins and acetylated lysines, leading to a reduction in transcriptional activity of key oncogenes. I-BET151 dihydrochloride is primarily utilized in cancer research and studies related to inflammatory diseases, making it a valuable tool for elucidating the role of BET proteins in various biological processes.
  16. BRD4 Inhibitor

    BRD4 Inhibitor-23 is a selective inhibitor targeting Bromodomain-containing protein 4 (BRD4), demonstrating potent inhibition with IC50 values of 6.21 nM for BRD4 BD-1 and 1.44 nM for BRD4 BD-2. This compound is valuable for studying the role of BRD4 in various cellular processes, including transcriptional regulation and cell cycle progression. Its applications extend to research in cancer biology and epigenetic regulation, making it a powerful tool for exploring therapeutic interventions.
  17. BPTF Bromodomain Inhibitor

    (S)-GSK1379725A is a selective inhibitor of the bromodomain and PHD finger containing transcription factor (BPTF) with a Kd of 2.8 μM. This compound demonstrates specificity for BPTF and does not significantly inhibit BRD4 bromodomain. Additionally, (S)-GSK1379725A exhibits antimalarial activity, making it a valuable tool for studying transcriptional regulation and potential therapeutic applications against malaria.
  18. EP300/CBP Inhibitor

    EP300/CBP-IN-2 is a potent inhibitor of the EP300 and CBP histone acetyltransferases, targeting the regulation of gene expression involved in cancer biology. This compound demonstrates significant biological activity in vivo, making it a valuable tool for investigating the role of these targets in tumorigenesis and potential therapeutic interventions. Its applications extend to cancer research, exploring novel strategies for epigenetic modulation in cancer treatment.
  19. BET Inhibitor

    BET-IN-9 is a Bromodomain and Extra-Terminal (BET) protein inhibitor that disrupts the interaction between BET proteins and acetylated lysines. This compound exhibits significant biological activity in blocking transcriptional regulation mediated by BET proteins. BET-IN-9 is utilized in research applications investigating cancer biology, inflammation, and other diseases associated with aberrant gene expression.
  20. BRD4-BD1 Inhibitor

    BRD4-BD1-IN-1 is a selective inhibitor of the BRD4-BD1 interaction, exhibiting an IC50 value of 38.20 μM. This compound disrupts the binding of bromodomain-containing protein 4 to acetylated lysines, thereby modulating transcriptional regulation. It is valuable for research into the role of BRD4 in cancer and other diseases, making it a useful tool for understanding epigenetic mechanisms and developing novel therapeutic strategies.
  21. BRD4 Inhibitor

    BRD4 Inhibitor-31 is a potent inhibitor of the bromodomain-containing protein 4 (BRD4), exhibiting inhibitory constants (Kis) of 0.234 μM and 0.295 μM for BRD4 bromodomains BD1 and BD2, respectively. This compound is utilized in research investigating the roles of BRD4 in inflammatory diseases, cancer progression, and AIDS pathogenesis. Its effectiveness in modulating BRD4 activity makes it a valuable tool for understanding the therapeutic potential in various disease contexts.
  22. Bromodomain Inhibitor

    Bromodomain inhibitor-12 (edisylate) is a selective bromodomain inhibitor that targets bromodomain-containing proteins, which play critical roles in the regulation of gene expression. This compound exhibits significant biological activity in modulating transcriptional processes related to autoimmune and inflammatory diseases. Its application in research can enhance the understanding of pathogenic mechanisms and facilitate the development of novel therapeutic strategies.
  23. CBP Inhibitor

    CBP-IN-1 is a potent inhibitor of the CREB-binding protein (CBP) with an IC50 of 1.5 nM. Additionally, it inhibits CBP BRET and BRD4(1), demonstrating IC50 values of 690 nM and 3100 nM, respectively. CBP-IN-1 is valuable for research applications focused on transcriptional regulation and related signal transduction pathways. Its selective inhibitory profile makes it a useful tool in the study of diseases associated with CBP dysregulation.
  24. SMARCA2/4 Inhibitor

    SMARCA2-IN-8 is a selective inhibitor of the SWI/SNF chromatin remodeling complexes SMARCA2 and SMARCA4, exhibiting potent activity with IC50 values of 5 nM and 6 nM, respectively. This compound effectively inhibits the proliferation of SMARCA2-mutated cancer cells, specifically SKMEL5, with an AAC50 of 5 nM and downregulates SMARCA2-dependent KRT80 gene expression at an AAC50 of 10 nM. SMARCA2-IN-8 demonstrates substantial antitumor efficacy and favorable pharmacokinetic properties in preclinical mouse models, making it a valuable tool for investigating chromatin remodeling in cancer research.
  25. p300/CBP Inhibitor

    KB528 is a selective inhibitor of the histone acetyltransferases p300 and CBP, demonstrating low nM IC50 values against these targets while sparing other members of the KAT family. This compound modulates the IRF4 transcriptional network, leading to decreased expression of key oncogenes such as IRF4, MYC, CAV2, and IGLL5, as well as reduced levels of IKZF3 protein. KB528 has been shown to effectively induce apoptosis in multiple myeloma cells, making it a valuable tool for research in multiple myeloma and related oncological studies.
  26. Bivalent BET Inhibitor

    GXH-II-052 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. It demonstrates strong binding affinity to BRD4 and BRDT family members, with Kd values ranging from 0.6 to 28 nM. GXH-II-052 exhibits significant antiproliferative activity and effectively reduces c-Myc expression. This compound is valuable for research in cancer biology and epigenetic modulation.
  27. PBRM1 Bromodomain Inhibitor

    PBRM1-BD2-IN-7 is a selective inhibitor targeting the bromodomain of polybromo-1 (PBRM1). With an IC50 value of 0.29 μM, it demonstrates significant inhibitory activity for PBRM1-BD2. This compound is primarily utilized in cancer research, facilitating studies on the role of PBRM1 in tumorigenesis and therapeutic resistance.
  28. PI3Kδ/BET Inhibitor

    PI3Kδ/BET-IN-1 is a selective inhibitor targeting both PI3Kδ and the bromodomain BRD4-BD1. With an IC50 of 112 nM for PI3Kδ and 19 nM for BRD4-BD1, this compound demonstrates potent antiproliferative effects in diffuse large B-cell lymphoma (DLBCL) cells. Its dual inhibition mechanism makes it a valuable tool for research into cancer biology and therapeutic development.
  29. Bet Inhibitor

    SDR-04 is a highly selective BET inhibitor that targets the BRD4-BD1 domain. It demonstrates potent inhibition of cell proliferation in the MV4;11 cancer cell line, making it a valuable tool for investigating the role of BET proteins in oncogenesis. SDR-04 can be utilized in various research applications aimed at understanding cancer biology and developing novel therapeutic strategies.
  30. Bivalent BET Inhibitor

    NC-III-49-1 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor with high affinity for BRD4 and BRDT family proteins, exhibiting Kd values of 0.095 nM for BRD4-1, 0.32 nM for BRD4-2, and 5.5 nM for BRDT-2, among others. This compound demonstrates notable antiproliferative activity and effectively reduces c-Myc expression. NC-III-49-1 is valuable for research in cancer biology and therapeutic studies targeting BET-related pathways.
  31. BRDT-BD2 Inhibitor

    CDD-1128 is a potent BRDT-BD2 inhibitor with an IC50 value of 521 nM. This compound is primarily utilized in studies focused on nonhormonal contraceptive agents, offering significant potential for advancing reproductive health research. Its selectivity toward the BRDT-BD2 domain makes it a valuable tool for elucidating the biological pathways involved in spermatogenesis.
  32. BRD4 Inhibitor

    TAT-PiET is a cell-penetrating peptide that specifically inhibits the extra-terminal (ET) domain of bromodomain-containing protein 4 (BRD4). This reagent demonstrates significant biological activity by reducing levels of both BRD4 and JMJD6, thereby effectively inhibiting cell proliferation. TAT-PiET exhibits resilience against endocrine resistance in estrogen receptor alpha (ERα)-positive breast cancer cells, making it a valuable tool for cancer research, particularly within the context of breast cancer studies.
  33. BET Inhibitor

    DDO-8926 is a potent and selective inhibitor of Bromodomain and Extra-Terminal (BET) proteins, targeting their role in the transcriptional regulation of pro-inflammatory cytokines. This compound has been shown to significantly alleviate mechanical hypersensitivity, making it an important tool for studying neuropathic pain. Its application in research can enhance the understanding of inflammation-related pain mechanisms and provide insights into potential therapeutic strategies.
  34. BRD7/BRD9 Inhibitor

    BRD7-IN-3 is a selective inhibitor targeting bromodomain-containing proteins BRD7 and BRD9, demonstrating IC50 values of 1.6 μM and 2.7 μM, respectively. This compound serves as a valuable tool in cancer research, particularly in studies focused on epigenetic regulation and transcriptional modulation. Its ability to disrupt the interaction between bromodomains and acetylated lysines makes it instrumental for investigations into the role of BRD7 and BRD9 in various disease pathways.
  35. PBRM1 Bromodomain Inhibitor

    PBRM1-BD2-IN-6 is a selective inhibitor of the PBRM1 bromodomain, exhibiting a potent IC50 value of 0.22 μM. This compound demonstrates significant antiproliferative activity and is valuable for investigating PBRM1-dependent cancer mechanisms. Its application in research may aid in the development of targeted therapies for cancers that rely on PBRM1 modulation.
  36. PBRM1 Bromodomain Inhibitor

    PBRM1-BD2-IN-1 is a selective inhibitor targeting the bromodomain of PBRM1, exhibiting significant binding affinity with a Kd of 0.7 μM and an IC50 of 0.2 μM. This compound demonstrates potent inhibitory activity, making it a valuable tool for probing the role of PBRM1 in cancer biology. PBRM1-BD2-IN-1 is suitable for research applications focused on cancer mechanisms and the therapeutic potential of bromodomain inhibition.
  37. SMARCA2 Inhibitor

    DCSM06 is a selective inhibitor of the bromodomain within the SWI/SNF chromatin remodeling complex SMARCA2, demonstrating an IC50 of 9.7 μM. This compound modulates chromatin accessibility and regulation of gene expression, making it a valuable tool for studying the role of SMARCA2 in various biological processes. Its application extends to cancer research and epigenetic regulation, providing insights into potential therapeutic strategies targeting chromatin remodeling pathways.
  38. BRDT-BD2/BRD4-BD2 Inhibitor

    CDD-1349 is a selective inhibitor of the BRDT-BD2 and BRD4-BD2 bromodomains, demonstrating a sixfold selectivity for BRDT-BD2 over BRD4-BD2. With an IC50 value of 22 nM against BRDT, this compound serves as a valuable tool in the exploration of nonhormonal contraceptive agents. Its targeted activity makes it suitable for research focused on reproductive biology and potential contraceptive development.
  39. Prodrug Of KMT9 Inhibitor

    KMT9-IN-1 is a prodrug of the KMT9 inhibitor that releases the active compound 7b upon hydrolysis by cellular esterases. This compound effectively targets KMT9, resulting in a reduction of H4K12me1 levels. KMT9-IN-1 exhibits notable antitumor activity against colon cancer and can be employed in research focused on prostate cancer and hepatocellular carcinoma.
  40. BET Inhibitor

    BET-IN-13 is a potent inhibitor of Bromodomain and Extraterminal (BET) proteins, with an IC50 value of 1.6 nM. This compound effectively decreases the mRNA expression levels of pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, and NOS2, demonstrating significant anti-inflammatory activity. BET-IN-13 is valuable for research involving acute liver injury and other inflammatory conditions.
  41. BRD Inhibitor

    CPI703 is a selective bromodomain (BRD) inhibitor that targets the BRD of the 5DBM complex. By binding to specific residues in the first domain, CPI703 disrupts protein-protein interactions, leading to the modulation of cellular processes linked to transcription regulation. This compound is utilized in various research applications, including studies on epigenetic regulation and the development of cancer therapeutics.
  42. BET Inhibitor

    RX-37 is a selective bromodomain and extraterminal (BET) inhibitor that targets BET bromodomain proteins, including BRD2, BRD3, and BRD4, with Ki values ranging from 3.2 to 24.7 nM. This compound demonstrates significant potential in cancer research by modulating gene expression pathways associated with oncogenesis. RX-37 is suitable for studies focused on the role of BET proteins in tumor biology and therapeutic interventions.
  43. BRD4 Inhibitor

    BRD4 Inhibitor-40 primarily targets the bromodomain protein BRD4, inhibiting its binding domains BRD4-BD1 and BRD4-BD2 with IC50 values of 16.1 nM and 142.18 nM, respectively. This compound effectively modulates the expression of c-Myc and p21, resulting in G1 phase cell cycle arrest. Additionally, BRD4 Inhibitor-40 has demonstrated efficacy in inhibiting Pkd1-null renal cystic epithelial cells and blocking renal cyst formation in both Madin-Darby canine kidney and embryonic kidney vesicle models, thus showcasing its potential in renal research applications.
  44. BRDT-BD2 Inhibitor

    CDD-1498 is a selective inhibitor of the bromodomain-containing protein BRDT-BD2, exhibiting an IC50 of 978 nM. This compound demonstrates significant potential for use in research focused on nonhormonal contraceptive agents, providing insights into the modulation of male fertility and reproductive biology. Its potency and specificity make it a valuable tool for investigating the role of BRDT-BD2 in these biological processes.
  45. CBP Bromodomain Inhibitor

    Y08262 is a potent and selective CBP bromodomain inhibitor, demonstrating remarkable specificity with an IC50 value of 73.1 nM. This compound is utilized in research focused on acute myeloid leukemia (AML), offering insights into the role of CBP bromodomain interactions in cancer biology. Its selective inhibition makes it a valuable tool for studying the therapeutic potential of targeting bromodomain-containing proteins in hematological malignancies.
  46. SMARCA2 Inhibitor

    SMARCA2-IN-2 is a specific inhibitor of SMARCA2, demonstrating an IC50 range of 101-500 µM. This compound is relevant for investigations into cancer biology, as it provides insights into the role of SMARCA2 in tumorigenesis. Its ability to selectively modulate SMARCA2 activity makes it a valuable tool for understanding epigenetic regulation in cancer research.
  47. BRD4 Inhibitor

    BRD4 Inhibitor-36 is a selective inhibitor of the BRD4 protein, which is implicated in various cancer pathways. This compound disrupts the interaction between BRD4 and acetylated histones, thereby influencing transcriptional regulation. BRD4 Inhibitor-36 is primarily utilized in cancer research to explore its effects on tumor growth and progression, making it a valuable tool for studies investigating the molecular mechanisms of malignancies.
  48. BRD4 Inhibitor

    BRD4-IN-10 is a selective inhibitor of Bromodomain-containing protein 4 (BRD4), exhibiting an IC50 of 13.5 nM. This compound demonstrates anti-inflammatory and anti-fibrotic activities, making it a valuable tool in studies related to renal fibrosis. It also possesses favorable metabolic stability and pharmacokinetic properties, enhancing its suitability for research applications in exploring BRD4-related pathways and therapeutic interventions.
  49. BRD4 Inhibitor

    Bi-magnolignan is an inhibitor of BRD4, a key regulator involved in the recognition of acetylated lysines on histones and non-histone proteins. This compound has been shown to induce DNA damage and promote apoptosis in cancer cells, specifically inhibiting the proliferation of HCT116 cells with an IC50 value of 2.9 μM. Bi-magnolignan may serve as a valuable tool for elucidating the role of BRD4 in cancer biology and for developing novel therapeutic strategies against BRD4-dependent malignancies.
  50. BRD4 BrD1 inhibitor

    Olinone is a selective inhibitor of the bromodomain-containing proteins BRD4 and BrD1. This compound has been shown to accelerate the differentiation of primary oligodendrocyte progenitors derived from mouse models, making it a valuable tool for studying oligodendrocyte development and associated neural pathways. Its specificity for BRD4 and BrD1 further supports its use in research focusing on epigenetic regulation and potential neurodegenerative disease mechanisms.

Items 1901-1950 of 2164

Page
per page
Set Descending Direction